Candida albicans – Page 2

Synergistic potential and apoptosis induction of Bunium persicum essential oil and its pure components, cuminaldehyde and γ-terpinene, in combination with fluconazole on Candida albicans isolates: in vitro and in silico evaluation

mycolabadmin

Researchers studied how an essential oil from black cumin seeds (Bunium persicum) and two of its key active components could work together with the antifungal drug fluconazole to fight Candida albicans infections, including drug-resistant strains. Using laboratory tests and computer modeling, they found that cuminaldehyde, one of the main components, was particularly effective when combined with fluconazole, killing yeast cells through multiple mechanisms. This suggests that natural plant compounds could be valuable partners with conventional antifungal medications to overcome drug resistance.

Efficacy of Rezafungin on Candida albicans Endophthalmitis in a Rabbit Model

mycolabadmin

Researchers tested a new antifungal drug called rezafungin against a serious eye infection caused by Candida fungus in rabbits. Rezafungin performed much better than two other commonly used antifungal drugs, completely eliminating the fungus from the eye while preventing infection-related damage. The drug’s ability to be given weekly instead of daily makes it more practical for treating patients with severe fungal eye infections.

Correction to: Candida albicans—A systematic review to inform the World Health Organization Fungal Priority Pathogens List

mycolabadmin

This is a correction notice to an important scientific review about Candida albicans, a common fungal infection that affects many people worldwide. The World Health Organization requested this systematic review to help prioritize which fungal diseases are most important to address globally. The correction simply fixes an author’s name that was misspelled in the original published version of the review.

Characterizing antimicrobial activity of environmental Streptomyces spp. and oral bacterial and fungal isolates from Canis familiaris and Felis catus

mycolabadmin

Researchers collected bacteria and fungi from the mouths of pet dogs and cats, as well as environmental soil bacteria, to search for natural antimicrobial compounds. They found that some of these microorganisms produce substances that can kill harmful bacteria like E. coli and fungi like Candida albicans, especially when combined with existing antifungal medications. Notably, one environmental bacterium (Streptomyces) produced a compound that was even effective against fungal strains resistant to common antifungal drugs, suggesting promising new treatment possibilities.

The ATO gene family governs Candida albicans colonization in the dysbiotic gastrointestinal tract

mycolabadmin

This study shows that the fungus Candida albicans uses a family of protein transporters called ATO to absorb acetate, a fatty acid produced by gut bacteria. When mice were treated with antibiotics that killed their beneficial bacteria, C. albicans could colonize their guts better if it had working ATO transporters. The research reveals that fungi have evolved special systems to take advantage of nutrients left behind when the normal gut bacteria are disrupted, which helps explain why fungal infections are more common after antibiotic use.

Effects of Short-Chain Fatty Acid Combinations Relevant to the Healthy and Dysbiotic Gut upon Candida albicans

mycolabadmin

Short-chain fatty acids produced by healthy gut bacteria appear to slow the growth and reduce the invasive characteristics of Candida albicans, a fungus that normally lives harmlessly in the gut but can cause infections when the microbiota is disrupted by antibiotics. This study tested whether healthy gut SCFA levels inhibit Candida more effectively than dysbiotic levels and found that the healthy SCFA mix was somewhat more effective at preventing fungal hyphal formation, which is important for tissue invasion. However, different Candida strains responded differently to the SCFAs, suggesting that individual variation affects how protective these bacterial metabolites can be.

Protein kinase A signaling regulates immune evasion by shaving and concealing fungal β-1,3-glucan

mycolabadmin

Candida albicans is a fungus that causes infections in humans. The fungus has developed a clever way to hide from our immune system by covering up a molecule on its surface called β-1,3-glucan that normally triggers immune responses. This study shows that the fungus masks this molecule through a combination of growing and dividing to create new surfaces, and then using enzymes to trim away exposed molecules. The research reveals that a specific cell signaling pathway controlled by lactate (a chemical found in our bodies) activates this masking behavior, helping the fungus evade immune recognition.

Multilocus sequence typing of Candida albicans isolates from wild and farm animals from southern Italy

mycolabadmin

Researchers studied a fungal pathogen called Candida albicans found in farm and wild animals in Italy to understand how it spreads between animals and humans. They used genetic analysis to compare isolates from laying hens, wild boars, and lizards with samples from infected humans around the world. The results showed that animal isolates were genetically similar to human clinical samples, suggesting animals could serve as reservoirs for this infection. This research highlights the importance of monitoring fungal diseases in animal populations as part of understanding disease transmission between animals and people.

Characterization of ORF19.7608 (PPP1), a biofilm-induced gene of Candida albicans

mycolabadmin

Researchers studied a gene called PPP1 in Candida albicans, a common fungal infection in hospitals. They found that this gene is highly active when the fungus forms protective biofilms on medical devices like catheters. Although the protein appears in a distinctive spotted pattern only during biofilm formation, removing this gene did not prevent biofilm formation or affect how the fungus responds to stress or antifungal drugs.

PTP1B deficiency in myeloid cells increases susceptibility to Candida albicans systemic infection by modulating antifungal immunity

mycolabadmin

This research shows that a protein called PTP1B plays an important role in protecting the body against dangerous yeast infections caused by Candida albicans. When this protein is missing from immune cells, mice become much more susceptible to severe fungal infections. The study found that PTP1B helps immune cells called macrophages and neutrophils kill fungi effectively, and when it’s absent, these immune cells work poorly. This discovery suggests that targeting PTP1B could be a new way to help patients fight off serious fungal infections.

Research Keyword: Candida albicans